Vigabatrin
Complex Partial Seizures
University of PennsylvaniaSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Complex Partial Seizures cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rwj-333369 SK Life Science, Inc. | Phase 3 | BB |
Carisbamate SK Life Science, Inc. | Phase 3 | BB |
Remegal Valexfarm | Phase 3 | BB |
Same molecule, other indications
Vigabatrin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →